A recent study reveals that people who discontinue blockbuster weight-loss injections like semaglutide or tirzepatide can put back on reduced body mass at a significantly accelerated pace than those who end conventional lifestyle programs.
Published data in a leading medical journal demonstrates that while overweight people can lose a large proportion of their body weight while undergoing treatment, the mass returns at an estimated rate of nearly a kilo each month after stopping.
"People purchasing such medications need to be informed of the danger of fast weight regain when the therapy ends," stated lead investigator Dr. Susan Jebb.
That rate of recovery implies a return to starting mass in about 18 months.
Weighing Approaches
The study, which examined dozens of studies involving thousands of patients, compared the effects of GLP-1 agonists with other pills.
Researchers point out that individuals who shed pounds through dieting generally see a slower creep back—perhaps 100 grams monthly—after stopping.
Explaining the Fast Regain
Doctors suggest the mode of action of the drugs is key to understanding the amplified regain.
The injections imitate a body's own chemical called glucagon-like peptide-1, which helps regulate hunger.
"Artificially providing GLP-1 concentrations far above than normal may cause the body to produce less of its endogenous GLP-1, and could reduce responsiveness to its effects," explained Dr. Adam Collins, a nutrition specialist.
"Stopping of this GLP-1 'fix' leads to hunger is uncontrolled, making overeating much more probable."
A Chronic Condition?
Medical guidelines advise the injections for people with weight-linked medical conditions, alongside prescribed diet and exercise modifications.
Professionals argue that, considering the high risk of relapse, the treatment should be considered life-long.
This perspective is reinforced by pharmaceutical companies, who state that the findings "underscore the chronic nature of excess weight," comparing it to managing conditions like hypertension.
Patient Experiences
Individuals who have discontinued the medication explain a powerful resurgence of hunger.
"I experienced a switch flipping and you're instantly starving," said a patient.
The struggle is compounded if users have not developed permanent dietary or behavioural changes during therapy.
Growing Interest
Figures suggest that millions of people in the UK have used weight-loss jabs in the past year, with desire being substantial.
- Adoption is higher among women than men.
- The middle-aged demographic shows the highest level of interest.
- Many access the medications through private healthcare rather than public health services.
Finally, clinicians caution that while the jabs are effective agents for shedding pounds, they are not a magic solution and maintained weight loss likely depends on integrated lifestyle management.
